The secret dialogue between tumour rigidity and its genes

An excellent phased structure with clear GO/NO-GO/PIVOT criteria is presented, enabling objective decision-making and resource conservation in the event of early failure.

The proposed causal chain is mechanistically grounded: it is supported by a robust literature (Totaro et al., 2017) demonstrating the inhibition of Notch by YAP/TAZ in response to mechanical signals. The extension to a multicellular 3D system represents a logical and important progression.

The use of unsupervised clustering on 300+ morphological features is a modern and potentially powerful approach for capturing complex phenotypes without a priori bias.

Clear upstream market: CROs (Charles River, Eurofins) and pharmaceutical companies (Novartis, Roche) in oncology would pay for a predictive 3D test of resistance to therapies targeting YAP/TAZ or Notch (e.g., TEAD inhibitors, gamma-secretase inhibitors). The market size is estimated at €50–80 million per year for multiplexed 3D profiling services in preclinical screening.

A clear and falsifiable mechanistic hypothesis is presented, with well-defined GO/NO-GO criteria, a feature that is rare and valued by reviewers for its scientific rigour.